Lenalidomid Sun

Lenalidomide, the active ingredient in Lenalidomid Sun, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is indicated for multiple myeloma, myelodysplastic syndromes with del(5q), mantle cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia in appropriate patients.

GNH USA supplies Lenalidomid Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in several hematologic malignancies and related disorders, targeting abnormal cell growth and immune dysregulation. - Multiple myeloma: improves response rates and prolongs survival in relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and cytopenias. - Mantle cell lymphoma: contributes to disease control when combined with other agents. - Follicular lymphoma: enhances remission duration in selected patients. - Chronic lymphocytic leukemia: adds therapeutic benefit in combination regimens.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Diarrhea: loose stools occurring during treatment. - Rash: mild skin eruptions or itching. - Nausea: occasional upset stomach. - Constipation: reduced bowel movements. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low white‑blood‑cell counts. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

Patients should be monitored for known risks and counseled on safety measures. - Pregnancy contraindication: drug is teratogenic; avoid use in pregnant women. - Thrombosis risk: assess need for prophylactic anticoagulation. - Renal impairment: adjust monitoring in patients with reduced kidney function. - Hepatic dysfunction: evaluate liver function before and during therapy. - Infection vigilance: monitor for signs of infection due to immunosuppression. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lenalidomide may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants: increased risk of bleeding when combined with lenalidomide.

Moderate Interactions (Monitor Closely): - Immunosuppressants: heightened infection risk. - P‑glycoprotein inhibitors: potential alteration of drug levels. - NSAIDs: may exacerbate renal toxicity. - Vaccines: live vaccines should be avoided during treatment. - Hormonal contraceptives: reduced efficacy; additional contraception recommended.